Privia Health Group, Inc. Form 8-K Summary
Business Context and Reporting Period
Privia Health Group, Inc. filed a Form 8-K under Item 5.02 and Item 7.01. The report date was January 25, 2024; the filing was signed January 29, 2024. The filing concerns a senior executive transition and does not report quarterly or annual operating results.
Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating metrics. It also does not provide a quantified estimate of the financial impact of the executive transition.
Material Changes
- Thomas Bartrum, Executive Vice President and General Counsel, will remain employed through a transition period from January 29, 2024 through May 31, 2024.
- Edward C. Fargis was appointed Secretary and Executive Vice President and General Counsel, effective January 29, 2024.
- Mr. Bartrum will continue receiving his current salary and benefits during the transition period and may receive his 2023 performance bonus if earned under applicable performance goals.
- Subject to continued employment, restrictive-covenant compliance, and execution of a release, Mr. Bartrum will receive separation benefits including 12 months of base salary, his 2024 target bonus, up to 12 months of COBRA-related benefit costs, and limited acceleration of equity awards.
- Vested stock options, including those accelerated at departure, will remain exercisable through their original expiration dates. Other unvested equity awards will be forfeited upon departure.
Outlook, Risks, Contingencies, and Unusual Items
The filing contains no business or financial guidance. The separation benefits are contingent on Mr. Bartrum completing the transition period, complying with restrictive covenants, timely electing COBRA coverage where applicable, and executing and not revoking a release of claims.
Mr. Bartrum reaffirmed non-compete obligations through May 31, 2025, and non-solicitation obligations through May 31, 2026. The filing does not quantify the expected cash or equity compensation expense associated with the agreement.
Investor Verification Items
- Review Exhibit 10.1 for the complete terms, definitions, conditions, and payment timing of the Transition Agreement.
- Verify the amount and eventual payment status of Mr. Bartrum’s 2023 bonus and 2024 target bonus.
- Assess the value and accounting treatment of salary continuation, COBRA benefits, and accelerated equity awards.
- Monitor any subsequent disclosure regarding the transition, executive compensation expense, or changes in legal and compliance leadership.